Last update: Sept. 19, 2016

Vilanterol Trifenatate

Very Low Risk for breastfeeding


Safe. Compatible.
Not risky for breastfeeding or infant.

Long-acting bronchodilator with a similar action than Salmeterol.

At latest update no published data on excretion into breast milk were found.

Plasma concentration after having inhaled bronchodilators is very low, so that a significant amount in the breast milk is not expected (Ellsworth 1994, McDonald 1996).
Its low oral bioavailability hinders the passage from ingested milk towards the infant’s plasma, except in preterm babies and immediate neonatal period, which may show an increased intestinal permeability.

Terbutaline, a molecule of the same family, is excreted in insignificant amounts in breast milk (Lindberg 1984).

Inhaled bronchodilators are preferred because of their lower doses (less risk of excretion into milk).

Alternatives

We do not have alternatives for Vilanterol Trifenatate since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Vilanterol Trifenatate in other languages or writings:

Group

Vilanterol Trifenatate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Vilanterol Trifenatate in its composition:

  • Breo Ellipta™. Contains other elements than Vilanterol Trifenatate in its composition
  • Relvar Ellipta™. Contains other elements than Vilanterol Trifenatate in its composition
  • Revinty™. Contains other elements than Vilanterol Trifenatate in its composition

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 27 %
Molecular weight 775 daltons
T1/2 1,5 - 2 hours

References

  1. Kelleher DL, Mehta RS, Jean-Francois BM, Preece AF, Blowers J, Crater GD, Thomas P. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS One. 2012 Abstract
  2. Nelson-Piercy C. Asthma in pregnancy. Thorax. 2001 Abstract Full text (link to original source) Full text (in our servers)
  3. McDonald CF, Burdon JG. Asthma in pregnancy and lactation. A position paper for the Thoracic Society of Australia and New Zealand. Med J Aust. 1996 Abstract
  4. Ellsworth A. Pharmacotherapy of asthma while breastfeeding. J Hum Lact. 1994 Abstract
  5. Lindberg C, Boréus LO, de Château P, Lindström B, Lönnerholm G, Nyberg L. Transfer of terbutaline into breast milk. Eur J Respir Dis Suppl. 1984 Abstract

Total visits

1,958

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) from Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM